PACB

Pacific Biosciences of California, Inc.

$2.24

-5.08%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument.

Source: Yahoo Finance
AI summary

Price & performance

1M-7.7%
3M+67.5%
YTD+27.4%
1Y+0.2%
52-week range—
Beta2.28
Full chart and returns against a benchmark

Q-Score

38/ 100

Quality against peers; 50 is the peer median.

Growth43
Risk36
Performance45
Valuation40
Profitability37
Leverage41
Sentiment32
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$160M+3.9%
Net income-$546.4M
Net margin-341.5%-140.3 pts
Historical fundamentals

Revenue exposure

56%of revenue from outside the US
Americas45%
EMEA28%
Asia Pacific27%
Regions, segments, customers and suppliers

Valuation

PACBIndustryP/E—29.61P/S4.313.49EV/EBITDA—18.38P/B—3.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 4next report
EPS estimate$-0.13
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate